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bDepartment of Radiology, Jewish General Hospital, McGill University, Montreal, CanadaAbstractPurpose: Multiple sclerosis diagnostic criteria include the presence of gadolinium-enhancing lesions when determining dissemination in
space and time. Gadolinium is expensive, increases scan time and patient discomfort, and can, rarely, cause serious adverse effects. Our
objective was to determine the usefulness of including gadolinium-enhanced images as part of a follow-up brain magnetic resonance imaging
(MRI) in patients with a clinically isolated syndrome.
Methods: Consecutive patients seen between 2008 and 2010 with a clinically isolated syndrome suggestive of multiple sclerosis were
prospectively enrolled, had a nonegadolinium-enhanced brain MRI, and consented to a follow-up gadolinium-enhanced brain MRI. The
primary outcome was a comparison of the number of patients diagnosed with multiple sclerosis compared with the number who would have
been diagnosed without the gadolinium-enhanced images.
Results: Twenty-one patients enrolled, and 2 withdrew. Follow-up MRIs were performed a median of 241 days after the initial MRI. Eleven
patients met the primary outcome and were diagnosed with multiple sclerosis: 6 as a result of a second clinical attack and 5 by using imaging
criteria for dissemination in space and time. If the gadolinium-enhanced images had not been obtained, then there would have been no change
in the primary outcome.
Conclusions: In Canadian centers with similar MRI waiting times to those in our study, the routine use of gadolinium as part of a follow-up
MRI in patients with suspected multiple sclerosis may not be clinically useful. Gadolinium-enhanced images could still be obtained on an as-
needed basis for specific clinical indications.ResumeObjet : Les criteres de diagnostic de la sclerose en plaques incluent la presence de lesions rehaussees par injection de gadolinium lorsqu’il
s’agit d’evaluer la dissemination spatiale et temporelle de la maladie. Toutefois, le recours au gadolinium est cou^teux, accro^ıt la duree de
l’examen et l’inconfort du patient et peut en de rares occasions entra^ıner des effets indesirables graves. Notre objectif consistait a mesurer
l’utilite du rehaussement des images par injection de gadolinium lors de l’examen d’imagerie par resonance magnetique (IRM) du cerveau
realise a des fins de suivi chez les patients presentant un syndrome cliniquement isole.
Methodes : Des patients ayant ete evalues de maniere consecutive entre 2008 et 2010 et presentant un syndrome cliniquement isole evocateur
de sclerose en plaques ont pris part a cette demarche prospective. Ils ont subi un examen du cerveau par IRM sans injection de gadolinium,
puis ont consenti a un examen de suivi par IRM rehaussee par injection de gadolinium. Les resultats visaient d’abord a comparer le nombre
de patients ayant rec¸u un diagnostic de sclerose en plaques avec le nombre de patients chez qui un diagnostic aurait ete pose si les images
n’avaient pas ete rehaussees par injection de gadolinium.
Resultats : Vingt et un patients ont participe a l’etude et deux se sont retires. Les examens d’IRM de suivi ont ete realises apres une periode
mediane de 241 jours suite au premier examen d’IRM. Onze patients ont obtenu un diagnostic de sclerose en plaques : six a la suite d’une
deuxieme poussee clinique et cinq en se fondant sur les criteres d’imagerie relatifs a la dissemination spatiale et temporelle des lesions.
Me^me sans images rehaussees par injection de gadolinium, le resultat principal serait demeure identique.
Conclusions : Dans les centres canadiens qui ont des temps d’attente pour l’IRM semblables a ceux de notre etude, l’injection systematique
de gadolinium dans le cadre de l’examen de suivi des patients chez qui on suspecte une sclerose en plaques pourrait ne pas s’averer utile sur* Address for correspondence: Fraser G. A. Moore, MD, Department of
Neurology, Jewish General Hospital, McGill University, 3755 Co^te-Sainte-
Catherine E-005, Montreal, QC H3T 1E2, Canada.
E-mail address: fraser.moore@mcgill.ca (F. G. A. Moore).
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359Gadolinium MRI in suspected MS / Canadian Association of Radiologists Journal 64 (2013) 358e362le plan clinique. Des images rehaussees par injection de gadolinium pourraient quand me^me e^tre realisees au besoin, en cas d’indications
cliniques precises.
 2013 Canadian Association of Radiologists. All rights reserved.
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based on the presence of neurologic symptoms and signs that
are ‘‘disseminated in time and space’’ [1,2]. The McDonald
criteria more fully integrated magnetic resonance imaging
(MRI) into the diagnostic scheme by permitting the diagnosis
of definite MS in a patient with a single clinical attack if the
MRI criteria were met for dissemination in space and time [3].
The McDonald criteria were revised in 2005 [4] and 2010 [5].
A patient with new symptoms suspicious for MS is considered
to have a clinically isolated syndrome (CIS) [6]. An MRI is
usually performed on a semi-urgent basis, and the results may
increase the suspicion for MS, especially if the MRI fulfills
criteria for dissemination in space. However, definite MS
cannot be diagnosed after a single attack unless either a new
gadolinium-enhancing lesion or a new T2 lesion is seen on
a follow-up scan [4] or if both gadolinium-enhancing and non-
enhancing lesions are seen on the original scan [5].
In many regions of Canada, there are long waiting times of
3-6 months or more for an MRI. Typically, the wait is longer
for scans with gadolinium because of the additional scan time
and the concern of possible anaphylactic reaction to the
gadolinium [7,8], such that many centers are reluctant to
schedule an MRI with gadolinium after regular working hours
or on weekends. It, therefore, is important to know whether or
not a follow-up MRI should be performed with gadolinium.
Published studies that analysed the use of MRI in patients
presenting with a CIS [9e13] have not specifically addressed
this question in general neurology practice populations [5]. The
studies were performed in MRI research units with the
requirement that follow-up scans be done at set time points. The
goal of this study was to evaluate the usefulness of gadolinium-
enhanced images as part of a follow-upMRI in the diagnosis of
patients with suspected MS in routine clinical practice.
Patients and Methods
Consecutive patients seen by the first author (F.G.A.M.)
between 2008 and 2010 with a CIS suggestive of MS were
prospectively enrolled. Subjects were recruited from the
emergency department and outpatient neurology clinics of
a 637-bed tertiary care teaching hospital. Inclusion criteria
were symptom onset in the previous year, a baseline MRI
(with no requirement for the number or distribution of
lesions), and age 18-65 years old. Exclusion criteria were the
presence of an alternative diagnosis or explanation for the
symptoms, a history of prior symptoms compatible with MS,
pregnancy, or a known allergy or intolerance to gadolinium.
Subjects who met the inclusion criteria were asked to
participate and signed a consent form. A follow-up MRI withgadolinium was then requested. Treatment decisions were
left to the discretion of the treating neurologist.
The time to the follow-up MRI was determined by the
normal radiology department waiting time. The specific MRI
sequences and parameters were the standard ones used by the
radiology department for this clinical situation. In otherwords,
we did not impose a specific imaging protocol other than to
require the use of gadolinium. The rationale for this was that
the study was not intended to assess the potential of MRI (the
‘‘best-case’’ scenario by using many different sequences),
rather, it was intended to be a study that examined the practical
usefulness of MRI (the ‘‘real-life’’ scenario). Images were
obtained on a 1.5-T scanner (Intera NT Release 12.1.5; Philips
Medical Systems, Eindhoven, Netherlands) with the following
sequences: sagittal T1W, sagittal dual echo, axial fluid-
attenuated inversion recovery, axial and sagittal T1-weighted
gadolinium-enhanced (0.1 mmol/kg of gadolinium verseta-
mide-diethylenetriaminepentacetate; BMEA Optimark Tyco
Healthcare, Mansfield, MA) (acquisition delay, 1 minute).
Standard parameters used during the study are provided in
Appendix 1. Radiologists were expected to report the results as
they would in everyday practice, without the typical restric-
tions of a clinical trial. EachMRIwas also reviewed by the first
author.
The primary outcome was the number of patients diag-
nosed with the 2005 McDonald MS criteria. This number was
compared with the number who would have been diagnosed
with the 2005 McDonald MS criteria if the gadolinium-
enhanced images had not been obtained. Secondary
outcome measures included the number of subjects who ful-
filled the diagnosis of clinically definite MS (Poser criteria)
[2] at last follow-up, the number of subjects who fulfilled the
diagnosis of definite MS when using the 2010 McDonald
criteria [5], and the time to receive the follow-up MRI.
Planned enrollment was 40-50 subjects, with a planned
preliminary analysis to be done after 20 subjects had received
their follow-up MRIs. The subjects were followed-up at least
every 6 months (the usual clinical practice in our clinic). Data
were analysed by using descriptive statistics according to the
outcome measures described above. The study was approved
by the research ethics committee of our hospital.
ResultsPrimary OutcomeA total of 25 patients were invited to participate. Two
patients refused, and 2 did not meet the inclusion criteria.
Twenty-one patients were enrolled, of whom 2 withdrew
Table 1
Baseline characteristics of the study subjects (n ¼ 19)
Mean age, y 35
% women 63




Spinal cord 11 (58)
Median time from symptom onset to baseline MRI, d 15
Mean no. (range) T2 lesions on baseline MRI 11 (0-27)a
McDonald 2005 (Barkhof) criteria positive for
dissemination in space, no. (%)
13 (68)
CIS ¼ clinically isolated syndrome; MRI ¼ magnetic resonance imaging;
ON ¼ optic neuritis.
a One patient with no lesions on a brain MRI had multiple spinal lesions.
Table 2
The diagnosis of multiple sclerosis in the study cohort (n ¼ 19)
Time CDMSa 2005 McDonald Criteria 2010 McDonald Criteria
Space Time MS Space Time MS
Baselineb 0 13 0 0 15 0 0
f/u MRIc 6 14 10 11 17 10 11
Last f/ud 6 14 10 11 17 10 11
CDMS ¼ clinically definite MS; f/u ¼ follow-up; MS ¼ multiple sclerosis;
MRI ¼ magnetic resonance imaging.
a From Ref. 2.
b At study enrollment.
c At the time of the follow-up, gadolinium-enhanced MRI.
d At the time of last clinical follow-up.
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tics of the 19 patients who completed the study are shown in
Table 1. Six of these 19 patients had begun treatment with
disease-modifying drugs a median of 160 days (range,
32-185 days) before the follow-up scan (4 interferon beta-1a
intramuscular, 1 interferon beta-1a subcutaneous, and 1
interferon beta-1b subcutaneous). The median time from
initial MRI to the follow-up scan was 241 days. At the time
of the follow-up scan, 11 patients had met the primary
outcome and were diagnosed with the 2005 McDonald MS
criteria (4 of whom were on treatment). In 6 cases, this was
a result of a second clinical attack (and, therefore, the
patients also fulfilled Poser criteria for clinically definite
MS), whereas, in 5 additional cases, the patients fulfilled the
2005 McDonald imaging criteria for dissemination in space
and time. If the gadolinium-enhanced images had not been
obtained, then there would have been no change in the
primary outcome, which meant that the same number of
patients would have been diagnosed with the 2005 Mc-
Donald MS criteria. Only 4 of the 19 patients who completed
the study actually had gadolinium-enhancing lesions on their
follow-up scan. Three of these patients had a second clinical
attack before the follow-up MRI and were diagnosed with
MS. The fourth patient fulfilled McDonald criteria for
dissemination in time and space without the gadolinium-
enhanced images. Recruitment stopped in June 2010, based
on these results.2005 vs 2010 McDonald CriteriaA single patient did not meet the 2005 McDonald criteria
for dissemination in space but did meet criteria for dissemi-
nation in time after the follow-upMRI. Evaluating the baseline
and follow-up scans by using the new, 2010, McDonald
criteria for dissemination in space resulted in no change (the
patient still did not meet criteria for dissemination in space).
Comparison of the different criteria is shown in Table 2.ComplicationsNo complications occurred as a result of the use of
gadolinium during the study. Fourteen of the 18 patients whoresponded to a brief questionnaire reported experiencing
little or no discomfort as a result of gadolinium use. All the
patients would be willing to undergo the test again.Follow-upAt the time of writing, the median follow-up time of
patients was 757 days beyond the date of the follow-up MRI
(range, 32-1168 days). No new clinical attacks had occurred
in those patients not diagnosed with MS at the time of the
follow-up MRI. Four patients diagnosed with MS at the time
of the follow-up MRI (all clinically definite MS) experienced
a further clinical attack.
Discussion
The goal of this prospective study was to evaluate the
usefulness of gadolinium-enhanced images as part of
a follow-up MRI in the diagnosis of patients with suspected
MS in routine clinical practice. The study was stopped early
because only 4 of 19 patients had gadolinium-enhancing
lesions on their follow-up MRI, and in none of these cases
did the presence of the gadolinium-enhancing lesions
contribute to the diagnosis of MS. We concluded that, in
Canadian centers with waiting times for MRI that are similar
to those in our study, the routine use of gadolinium as part of
a follow-up MRI in patients with a CIS and suspected MS
may not be clinically useful. Gadolinium-enhanced MRI
images could still be requested for other specific indications,
as discussed below.
Results of previous studies have suggested that gadoli-
nium enhancement may not be necessary when obtaining
a follow-up MRI and that a new T2 lesion would be suffi-
cient for dissemination in time [12,13]. However, these were
retrospective studies that used existing cohorts from MRI
research units, and the usefulness of gadolinium was not the
primary outcome measure. Our study was performed
prospectively and more closely approximates clinical prac-
tice because it used routine MRI performed in a general
hospital radiology department and had no set time points.
Weaknesses of our study are that it was performed at a single
center with a modest number of patients. We had originally
planned to recruit 40-50 subjects, but, based on the planned
preliminary analysis, we thought that recruiting additional
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not control for differences between individual radiologists or
calculate interobserver and intraobserver variability in their
assessment of lesions. Such variability is part of the ‘‘real-
life’’ practice that we wanted to assess. For the same reason
we did not impose a specific imaging protocol other than to
require the use of gadolinium, as discussed in the methods.
Finally, we did not control for treatment. However, there was
only a single patient for whom treatment may possibly have
prevented the diagnosis of MS because 4 of 6 treated patients
met the primary outcome measure, whereas a fifth patient
was only treated for 1 month.
This study was designed and performed before the
publication of the 2010 revisions to the McDonald criteria.
These criteria no longer require a follow-up MRI to
demonstrate dissemination in time if there are both T2 and
gadolinium-enhancing lesions on the initial scan. Although
in theory this allows for a faster diagnosis of MS, in routine
clinical practice, it may not be useful for 2 reasons. The first
is the difficulty in performing a gadolinium-enhanced MRI in
some practice settings. The second reason is that many
patients who present with a CIS will not have a gadolinium-
enhancing lesion on their initial scan. Pooled data from
clinical trials in CIS show that only 42% of patients have
a gadolinium-enhancing lesion on their initial scan [14e17].
Therefore, in many patients, a follow-up scan will still be
necessary, and the results of this study are still relevant.
Some researchers would also argue that there are other
uses for gadolinium-enhanced MRI in patients with sus-
pected MS. For example, gadolinium may be useful in the
differential diagnosis of unusual appearing central nervous
system white matter lesions [18]. However, in this situation
images with gadolinium could be requested on an as-needed
basis and would not need to be done routinely (in our study,
the gadolinium images did not lead to the consideration of
any alternative diagnoses). There also is some evidence that
the presence of gadolinium-enhancing lesions on MRI
provides prognostic information [19]. However, correlations
between imaging parameters and prognosis in a cohort of
patients can be difficult to apply to an individual patient, and
the routine use of gadolinium enhancement as a prognostic
indicator is probably not warranted.
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Standard imaging parameters used during the study were the following:
1. SURVEY T1 FFE: FOV 240, TR/TE 15/5.2, MATRIX 256/126, 3 PLANES at 3 SLICES thk/gap 10/10 mm, NSA 1, FFE.
2. SAG T1: FOV 250, TR/TE 596/15, MATRIX 268/217, 22 SLICES thk/gap 5/1.0 mm, NSA 2, SE, SCAN TIME 4:20.
3. SAG DE: FOV 250, TR/TE 4212/ (23/120), MATRIX 296/240, 26 SLICES thk/gap 3/1.0 mm, NSA 2, TSE, SCAN TIME 5:41.
4. AX T2 FLAIR: FOV 230, TR/TE 11000/140, TI 140 ms, MATRIX 244/156, 26 SLICES thk/gap 5/1.0 mm, NSA 2, IR-TSE, SCAN TIME 5:08.
5. AX DIFF SSH: FOV 230, TR/TE 4195/86, MATRIX 124/98, 25 SLICES thk/gap 5/1.0 mm, NSA 1, SE-EPI, SCAN TIME 0:54 seconds.
6. AX T1 POST: FOV 230, TR/TE 555/12, MATRIX 256/180, 25 SLICES thk/gap 5/1.0 mm, NSA 2, SE, SCAN TIME 3:21.
7. SAG T1 POST: FOV 250, TR/TE 596/15, MATRIX 268/217, 22 SLICES thk/gap 5/.5 mm, NSA 2, SE, SCAN TIME 4:20.
Scan times are in the format of min:sec.
AX ¼ axial; DE ¼ dual echo; FFE ¼ fast field echo; FLAIR ¼ fluid attenuated inversion recovery; FOV ¼ field of view; IR ¼ inversion recovery; NSA ¼
number of signal averages; POST ¼ post contrast; SAG ¼ sagittal; SE ¼ spin echo; SE-EPI ¼ spin echo-echo planar imaging; SSH ¼ single shot; Thk ¼
thickness (mm); TSE ¼ turbo spin echo.
Appendix 1
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